|
SERA Prognostics, Inc. (SERA) DCF -Bewertung
US | Healthcare | Medical - Diagnostics & Research | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Sera Prognostics, Inc. (SERA) Bundle
Verbessern Sie Ihre Anlagestrategien mit dem (SERA) DCF -Taschenrechner! Verwenden Sie reale Finanzdaten aus SERA -Prognostik, passen Sie Wachstumsprojektionen und Kosten an und beobachten Sie sofort, wie sich diese Modifikationen auf den inneren Wert von (SERA) auswirken.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .1 | .3 | .3 | .4 | .7 | 1.0 | 1.4 | 2.0 |
| Revenue Growth, % | 0 | -30.56 | 228 | 226.83 | 14.18 | 45.91 | 45.91 | 45.91 | 45.91 | 45.91 |
| EBITDA | -13.6 | -17.1 | -33.6 | -42.9 | -35.3 | -.4 | -.7 | -1.0 | -1.4 | -2.0 |
| EBITDA, % | -37786.11 | -68456 | -40980.49 | -16010.07 | -11531.7 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .9 | .9 | .7 | 1.2 | .9 | .4 | .7 | 1.0 | 1.4 | 2.0 |
| Depreciation, % | 2627.78 | 3580 | 803.66 | 454.48 | 294.12 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -14.5 | -18.0 | -34.3 | -44.1 | -36.2 | -.4 | -.7 | -1.0 | -1.4 | -2.0 |
| EBIT, % | -40413.89 | -72036 | -41784.15 | -16464.55 | -11825.82 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 21.4 | 13.5 | 105.1 | 82.7 | 49.1 | .4 | .7 | 1.0 | 1.4 | 2.0 |
| Total Cash, percent | .1 | .1 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | 3.1 | 6.1 | 11.5 | .3 | .4 | .6 | .9 | 1.3 |
| Account Receivables, % | 2.78 | 8 | 3832.93 | 2280.97 | 3748.37 | 62.16 | 62.16 | 62.16 | 62.16 | 62.16 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0.00277778 | 0 | 0 | 0.000373134328 | 0 | 0.000630182421 | 0.000630182421 | 0.000630182421 | 0.000630182421 | 0.000630182421 |
| Accounts Payable | .7 | .4 | 1.2 | 1.5 | 1.0 | .4 | .7 | 1.0 | 1.4 | 2.0 |
| Accounts Payable, % | 2077.78 | 1764 | 1459.76 | 577.61 | 341.83 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.1 | -.1 | -1.3 | -.8 | -.1 | -.4 | -.6 | -.8 | -1.2 | -1.8 |
| Capital Expenditure, % | -302.78 | -596 | -1590.24 | -295.15 | -41.83 | -88.37 | -88.37 | -88.37 | -88.37 | -88.37 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -18.0 | -19.6 | -35.5 | -44.2 | -36.2 | -.4 | -.7 | -1.0 | -1.4 | -2.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -16.4 | -19.2 | -38.5 | -46.4 | -41.3 | 10.2 | -.5 | -.7 | -1.1 | -1.5 |
| WACC, % | 7.81 | 7.81 | 7.81 | 7.81 | 7.81 | 7.81 | 7.81 | 7.81 | 7.81 | 7.81 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 6.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -2 | |||||||||
| Terminal Value | -27 | |||||||||
| Present Terminal Value | -19 | |||||||||
| Enterprise Value | -12 | |||||||||
| Net Debt | -2 | |||||||||
| Equity Value | -10 | |||||||||
| Diluted Shares Outstanding, MM | 31 | |||||||||
| Equity Value Per Share | -0.32 |
What You Will Get
- Editable Forecast Inputs: Easily adjust key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Sera Prognostics, Inc.'s (SERA) financial data pre-loaded to facilitate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically for you.
- Customizable and Professional: A refined Excel model that can be tailored to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Customizable Forecast Inputs: Adjust essential parameters such as revenue growth, EBITDA %, and capital expenditures tailored for Sera Prognostics, Inc. (SERA).
- Instant DCF Valuation: Automatically computes intrinsic value, NPV, and other financial metrics with precision.
- High-Precision Accuracy: Leverages Sera Prognostics' real-world financial data for credible valuation results.
- Effortless Scenario Analysis: Easily explore various assumptions and evaluate different outcomes.
- Efficiency-Boosting Tool: Streamline your workflow by avoiding the complexity of building valuation models from the ground up.
How It Functions
- Download: Obtain the pre-configured Excel file containing Sera Prognostics, Inc.'s (SERA) financial metrics.
- Customize: Modify projections, including revenue growth rates, EBITDA percentages, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various forecasts and evaluate results immediately.
- Make Decisions: Leverage the valuation findings to inform your investment choices.
Why Choose This Calculator for Sera Prognostics, Inc. (SERA)?
- Accurate Data: Utilize real Sera Prognostics financials for dependable valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-constructed calculations streamline the process, so you don’t have to start from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the healthcare sector.
- User-Friendly: Easy-to-navigate layout and clear, step-by-step guidance make it accessible for all users.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Sera Prognostics stock (SERA).
- Financial Analysts: Enhance valuation processes with pre-built financial models tailored for Sera Prognostics.
- Consultants: Provide clients with accurate valuation insights on Sera Prognostics quickly and effectively.
- Business Owners: Gain insights into how companies like Sera Prognostics are valued to inform your own business strategies.
- Finance Students: Explore valuation techniques using real-world data and case studies related to Sera Prognostics.
What the Template Contains
- Pre-Filled DCF Model: Sera Prognostics’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Sera Prognostics’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.